|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The ability to counteract PPARgamma suggests that gammaORF4 plays a role in the pathogenesis of colorectal cancers.
|
15857827 |
2005 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that PPARgamma gene polymorphism may be implicated with the development of colorectal cancers, in which K-ras gene is not mutated.
|
11956653 |
2002 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Each colorectal carcinoma cell line expressed PPARgamma.
|
12711249 |
2003 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we evaluated the association between colorectal cancer and specific tumor mutations and the Pro12Ala (P12A) PPARgamma polymorphism.
|
16489531 |
2006 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to evaluate whether EP(1-4) subtype, PPAR gamma receptor and COX-1/COX-2 expression in colorectal cancer are related to tumor-specific mortality.
|
17290397 |
2007 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
On the contrary, two other SNPs, PLA2G2A c.435+230C>T and PPARG c.1431C>T (p.His477His), were associated with a decrease in CRC risk.
|
18992148 |
2008 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese.
|
16965392 |
2006 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the relationship between UHRF1 and PPARG may have a relevant role in CRC progression.
|
22286757 |
2012 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This is the first report that IL6, IL8, and PPARG genes are important in relation to inflammation-related risk of sporadic CRC.
|
12839942 |
2003 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In summary, we identified a panel of proteins correlated with PPARγ expression that could be associated with CRC unveiling new pathways to be investigated for the selection of novel potential prognostic/predictive biomarkers and/or therapeutic targets.
|
27499265 |
2016 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Red meat intake, CYP2E1 and PPARγ polymorphisms, and colorectal cancer risk.
|
30489355 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the Ala allele of the PPARgamma P12A polymorphism might be a protective factor for colorectal cancer, but a risk factor for gastric cancer.
|
20596649 |
2010 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PPARgamma agonists have been shown to reduce the growth of colorectal carcinoma cells in culture and in xenograft models.
|
17390024 |
2007 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we found that 15-hydroxy-eicosatetraenoic acid (15S-HETE), an endogenous ligand for PPARgamma, was significantly decreased in the serum of patients with colorectal cancer.
|
14566836 |
2003 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, SOX9, β-catenin and PPARγ expression levels are deregulated in the CRC tissue, and in colon cancer cell lines ligand-dependent PPARγ activation unevenly influences SOX9 and β-catenin expression and subcellular localization, suggesting a variable mechanistic role in colon carcinogenesis.
|
23583560 |
2013 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ensemble of gene signatures identifies novel biomarkers in colorectal cancer activated through PPARγ and TNFα signaling.
|
24133572 |
2013 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The current meta-analysis has established that ADH1B (rs1229984) and PPARG (rs1801282) are two risk variants of CRC.
|
24552298 |
2014 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Thus, codeficiency of Cav1 and adenomatous polyposis coli facilitated formation of CRC, and activation of PPARg may offer novel strategies for treatment of CRC.
|
23640045 |
2013 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This study shows that PPARgamma agonists up-regulate KLF4 expression in receptor-dependent manner, and KLF4 was identified as a novel transcription factor that controls NAG-1 promoter activity in human and mouse colorectal cancers.
|
20385121 |
2010 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results provide new evidence of association between PPARG variants and colorectal cancer risk.
|
24045924 |
2013 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
RT-PCR and Western blot analysis showed that both human CRC cell lines expressed PPARgamma mRNA and protein.
|
16520894 |
2006 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The combination of resveratrol with a PPARγ agonist could be a promising pharmacological approach for treatment of colorectal cancer.
|
24975132 |
2014 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interactions of peroxisome proliferator-activated receptor {gamma} and diet in etiology of colorectal cancer.
|
15894676 |
2005 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARγ/OCTN2 pathway.
|
25075794 |
2014 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR(gamma)) ligands inhibit cell growth of colorectal cancer cells in most experimental models, but no significant effect could be observed in patients with colorectal cancer.
|
15911106 |
2005 |